Equities analysts expect that TAIWAN LIPOSOME/S (NASDAQ:TLC) will post earnings of ($0.22) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for TAIWAN LIPOSOME/S’s earnings, with estimates ranging from ($0.27) to ($0.20). TAIWAN LIPOSOME/S reported earnings of ($0.17) per share in the same quarter last year, which would suggest a negative year over year growth rate of 29.4%. The business is scheduled to issue its next quarterly earnings report on Monday, April 6th.
On average, analysts expect that TAIWAN LIPOSOME/S will report full year earnings of ($0.83) per share for the current year, with EPS estimates ranging from ($0.94) to ($0.74). For the next fiscal year, analysts forecast that the company will report earnings of ($1.19) per share, with EPS estimates ranging from ($1.39) to ($0.86). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow TAIWAN LIPOSOME/S.
A number of equities analysts recently weighed in on TLC shares. Zacks Investment Research raised shares of TAIWAN LIPOSOME/S from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research note on Saturday, October 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TAIWAN LIPOSOME/S in a research note on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of TAIWAN LIPOSOME/S in a research report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $9.44.
An institutional investor recently raised its position in TAIWAN LIPOSOME/S stock. Millennium Management LLC increased its position in TAIWAN LIPOSOME/S (NASDAQ:TLC) by 564.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 92,915 shares of the company’s stock after purchasing an additional 112,915 shares during the quarter. Millennium Management LLC owned approximately 0.29% of TAIWAN LIPOSOME/S worth $474,000 as of its most recent SEC filing. 2.11% of the stock is currently owned by hedge funds and other institutional investors.
TAIWAN LIPOSOME/S Company Profile
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.
Further Reading: Understanding Specialty Certificates of Deposit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.